Literature DB >> 11996403

Risk factors for severe respiratory syncytial virus infection in infants.

Y Aujard1, B Fauroux.   

Abstract

Severe respiratory syncytial virus (RSV) disease is associated with unacceptable morbidity and mortality in children, especially in young children. Underlying conditions including prematurity with or without bronchopulmonary dysplasia, congenital heart disease, immunosuppression or another underlying respiratory condition, such as cystic fibrosis, increase the risk of contracting and developing severe RSV disease. Environmental factors such as crowding, day-care attendance, and exposure to passive smoke can increase the risk of severe RSV disease. Children with severe RSV disease often require intensified medical care, including hospitalization, which places a burden on the child, the family, and the health care system. There are currently no effective curative treatments for severe RSV disease. Preventive measures, such as infection control and prophylaxis, appear to be the best options in the management of RSV disease in these high-risk patients.

Entities:  

Mesh:

Year:  2002        PMID: 11996403

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  21 in total

1.  Differential expression of ovine innate immune genes by preterm and neonatal lung epithelia infected with respiratory syncytial virus.

Authors:  Kenji Kawashima; David K Meyerholz; Jack M Gallup; Branka Grubor; Tatjana Lazic; Howard D Lehmkuhl; Mark R Ackermann
Journal:  Viral Immunol       Date:  2006       Impact factor: 2.257

2.  Verdinexor (KPT-335), a Selective Inhibitor of Nuclear Export, Reduces Respiratory Syncytial Virus Replication In Vitro.

Authors:  Patricia A Jorquera; Cynthia Mathew; Reena Ghildyal; Jennifer Pickens; Colin Williams; Jasmina M Luczo; Sharon Tamir; Ralph A Tripp
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

3.  Severe respiratory syncytial virus bronchiolitis in children: from short mechanical ventilation to extracorporeal membrane oxygenation.

Authors:  Cyril Flamant; Fazia Hallalel; Paul Nolent; Jean-Yves Chevalier; Sylvain Renolleau
Journal:  Eur J Pediatr       Date:  2004-11-25       Impact factor: 3.183

Review 4.  Current perspectives on the prevention and management of chronic lung disease in preterm infants.

Authors:  Prakesh S Shah
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 5.  Lamb model of respiratory syncytial virus-associated lung disease: insights to pathogenesis and novel treatments.

Authors:  Mark R Ackermann
Journal:  ILAR J       Date:  2014

Review 6.  Induction of protective effector immunity to prevent pathogenesis caused by the respiratory syncytial virus. Implications on therapy and vaccine design.

Authors:  Janyra A Espinoza; Susan M Bueno; Claudia A Riedel; Alexis M Kalergis
Journal:  Immunology       Date:  2014-09       Impact factor: 7.397

Review 7.  Clinical relevance of prevention of respiratory syncytial virus lower respiratory tract infection in preterm infants born between 33 and 35 weeks gestational age.

Authors:  X Carbonell-Estrany; L Bont; G Doering; J-B Gouyon; M Lanari
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-07-16       Impact factor: 3.267

8.  Expression of select immune genes (surfactant proteins A and D, sheep beta defensin 1, and toll-like receptor 4) by respiratory epithelia is developmentally regulated in the preterm neonatal lamb.

Authors:  David K Meyerholz; Kenji Kawashima; Jack M Gallup; Branka Grubor; Mark R Ackermann
Journal:  Dev Comp Immunol       Date:  2006-02-10       Impact factor: 3.636

9.  A case-crossover study of wintertime ambient air pollution and infant bronchiolitis.

Authors:  Catherine Karr; Thomas Lumley; Kristen Shepherd; Robert Davis; Timothy Larson; Beate Ritz; Joel Kaufman
Journal:  Environ Health Perspect       Date:  2006-02       Impact factor: 9.031

10.  Pediatric infectious diseases: getting research evidence into practice and generation of new evidence.

Authors:  Hans Van Rostenberghe
Journal:  Front Pediatr       Date:  2014-12-08       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.